Regeneron

Regeneron Pharmaceuticals is a leading biotechnology company that focuses on the discovery, development, and commercialization of medicines for serious medical conditions. They generate revenue primarily through the sale of their innovative drugs, such as EYLEA for eye diseases and Dupixent for allergic diseases, as well as through strategic collaborations and licensing agreements. Founded in 1988, Regeneron has a rich history of scientific breakthroughs, including the development of the VelocImmune technology, which accelerates the creation of fully human antibodies.

Recent Posts by Regeneron

1-20 of 325